XML 73 R53.htm IDEA: XBRL DOCUMENT
v3.25.0.1

SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Condensed Financial Information Disclosure [Abstract] |
Condensed Statements of Operations | BeiGene, Ltd. Financial Information of Parent Company Condensed Statements of Operations (Amounts in thousands of U.S. Dollars (“$”))
|  | Year Ended December 31,
|  | 2024 |  | 2023 |  | 2022
|  | $ |  | $ |  | $
Operating expenses |  |  |  |  |  |
Research and development |  | 353,903 |  |  | 326,560 |  |  | 637,152 |
Selling, general and administrative |  | 357,103 |  |  | 304,543 |  |  | 228,801 |
Total operating expenses |  | 711,006 |  |  | 631,103 |  |  | 865,953 |
Loss from operations |  | (711,006) |  |  | (631,103) |  |  | (865,953) |
Interest income, net |  | 3,101 |  |  | 48,982 |  |  | 39,585 |
Other income (expense), net |  | 63,522 |  |  | (297,856) |  |  | (1,173,306) |
Loss before income taxes |  | (644,383) |  |  | (879,977) |  |  | (1,999,674) |
Income tax expense |  | 403 |  |  | 1,731 |  |  | 4,141 |
Net loss |  | (644,786) |  |  | (881,708) |  |  | (2,003,815) |
Condensed Statements of Comprehensive Loss | BeiGene, Ltd. Financial Information of Parent Company Condensed Statements of Comprehensive Loss (Amounts in thousands of U.S. Dollars (“$”))
|  | Year Ended December 31,
|  | 2024 |  | 2023 |  | 2022
|  | $ |  | $ |  | $
Net loss |  | (644,786) |  |  | (881,708) |  |  | (2,003,815) |
Other comprehensive (loss) income, net of tax of nil: |  |  |  |  |  |
Foreign currency translation adjustments |  | (47,565) |  |  | (25,464) |  |  | (90,421) |
Pension liability adjustments, net |  | (1,942) |  |  | (5,611) |  |  | 365 |
Unrealized holding gain (loss), net |  | (35) |  |  | 9,046 |  |  | (5,311) |
Comprehensive loss |  | (694,328) |  |  | (903,737) |  |  | (2,099,182) |
Condensed Balance Sheets | BeiGene, Ltd. Financial Information of Parent Company Condensed Balance Sheets (Amounts in thousands of U.S. Dollars (“$”))
|  | As of December 31,
|  | 2024 |  | 2023
|  | $ |  | $
Assets |  |  |  |
Current assets: |  |  |  |
Cash and cash equivalents |  | 400,135 |  |  | 723,964 |
Prepaid expenses and other current assets |  | 249,016 |  |  | 785,471 |
Total current assets |  | 649,151 |  |  | 1,509,435 |
Loans to subsidiaries |  | 1,731,266 |  |  | 2,030,249 |
Investment in wholly owned subsidiaries |  | 2,081,335 |  |  | 1,207,352 |
Other non-current assets |  | 114,728 |  |  | 69,361 |
Total assets |  | 4,576,480 |  |  | 4,816,397 |
Liabilities and shareholders’ equity |  |  |  |
Current liabilities: |  |  |  |
Accrued expenses and other payables |  | 424,111 |  |  | 197,289 |
Indebtedness to subsidiaries |  | — |  |  | 362,917 |
Short-term debt |  | 762,146 |  |  | 547,215 |
Total current liabilities |  | 1,186,257 |  |  | 1,107,421 |
Other long-term liabilities |  | 58,000 |  |  | 171,649 |
Total liabilities |  | 1,244,257 |  |  | 1,279,070 |
Total shareholders’ equity |  | 3,332,223 |  |  | 3,537,327 |
Total liabilities and shareholders’ equity |  | 4,576,480 |  |  | 4,816,397 |
Condensed Statements of Cash Flows | BeiGene, Ltd. Financial Information of Parent Company Condensed Statements of Cash Flows (Amounts in thousands of U.S. Dollars (“$”))
|  | Year Ended December 31,
|  | 2024 |  | 2023 |  | 2022
|  | $ |  | $ |  | $
Cash flows from operating activities: |  |  |  |  |  |
Net loss |  | (644,786) |  |  | (881,708) |  |  | (2,003,815) |
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |
Acquired in-process research and development |  | — |  |  | 15,000 |  |  | — |
Amortization of research and development cost share liability |  | (73,226) |  |  | (55,294) |  |  | (96,402) |
Unrealized (gains) losses in subsidiaries |  | (85,471) |  |  | 237,351 |  |  | 932,071 |
Other items, net |  | 31,651 |  |  | (374,370) |  |  | (596,496) |
Changes in operating assets and liabilities: |  |  |  |  |  |
Prepaid expenses and other current assets |  | 1,053 |  |  | 30,519 |  |  | 6,671 |
Accrued expenses and other payables |  | 627,307 |  |  | (140,126) |  |  | 875,826 |
Net cash used in operating activities |  | (143,472) |  |  | (1,168,628) |  |  | (882,145) |
Cash flows from investing activities: |  |  |  |  |  |
Purchases of short-term investments |  | — |  |  | (2,075) |  |  | (1,485) |
Proceeds from sale or maturity of short-term investments |  | 2,628 |  |  | 552,000 |  |  | 1,487,028 |
Purchase of in-process research and development |  | — |  |  | (15,000) |  |  | (75,000) |
Investment in subsidiaries |  | (406,624) |  |  | (883,328) |  |  | (2,675,908) |
Other investing activities |  | (37,120) |  |  | 188,656 |  |  | 79,004 |
Net cash used in investing activities |  | (441,116) |  |  | (159,747) |  |  | (1,186,361) |
Cash flows from financing activities: |  |  |  |  |  |
Proceeds from short-term loans |  | 813,058 |  |  | 547,842 |  |  | 296,188 |
Repayment of short-term loans |  | (593,898) |  |  | (293,002) |  |  | (247,460) |
Proceeds from option exercises and employee share purchase plan |  | 45,371 |  |  | 55,712 |  |  | 46,965 |
Net cash provided by financing activities |  | 264,531 |  |  | 310,552 |  |  | 95,693 |
Effect of foreign exchange rate changes, net |  | (4,356) |  |  | — |  |  | — |
Net decrease in cash, cash equivalents, and restricted cash |  | (324,413) |  |  | (1,017,823) |  |  | (1,972,813) |
Cash, cash equivalents, and restricted cash, beginning of year |  | 724,548 |  |  | 1,742,371 |  |  | 3,715,184 |
Cash, cash equivalents, and restricted cash, end of year |  | 400,135 |  |  | 724,548 |  |  | 1,742,371 |

X
- References No definition available. + Details
Name: | srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract
Namespace Prefix: | srt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | srt_CondensedStatementOfComprehensiveIncomeTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedCashFlowStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration